173 related articles for article (PubMed ID: 29317111)
1. Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR
Anzueto A; Calverley PMA; Mueller A; Metzdorf N; Haensel M; Jardim JR; Pizzichini E; Giraldo H; Ramirez-Venegas A; Giugno ER
Arch Bronconeumol (Engl Ed); 2018 Mar; 54(3):140-148. PubMed ID: 29317111
[TBL] [Abstract][Full Text] [Related]
2. TIOtropium Safety and Performance In Respimat
Zhong N; Moon HS; Lee KH; Mahayiddin AA; Boonsawat W; Isidro MG; Bai C; Mueller A; Metzdorf N; Anzueto A
Respirology; 2016 Nov; 21(8):1397-1403. PubMed ID: 27490162
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.
Dahl R; Calverley PM; Anzueto A; Metzdorf N; Fowler A; Mueller A; Wise R; Dusser D
BMJ Open; 2015 Dec; 5(12):e009015. PubMed ID: 26715479
[TBL] [Abstract][Full Text] [Related]
4. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
[TBL] [Abstract][Full Text] [Related]
5. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR
Wise RA; Calverley PM; Carter K; Clerisme-Beaty E; Metzdorf N; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2018; 13():605-616. PubMed ID: 29497289
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.
Wise R; Calverley PM; Dahl R; Dusser D; Metzdorf N; Müller A; Fowler A; Anzueto A
NPJ Prim Care Respir Med; 2015 Nov; 25():15067. PubMed ID: 26540491
[TBL] [Abstract][Full Text] [Related]
7. Tiotropium Respimat inhaler and the risk of death in COPD.
Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
[TBL] [Abstract][Full Text] [Related]
8. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
[TBL] [Abstract][Full Text] [Related]
9. Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD.
Calverley PM; Anzueto AR; Dusser D; Mueller A; Metzdorf N; Wise RA
Int J Chron Obstruct Pulmon Dis; 2018; 13():1297-1308. PubMed ID: 29719385
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Two Tiotropium Formulations: A Retrospective Cohort Study.
Spila-Alegiani S; Trotta F; Da Cas R; Rossi M; Venegoni M; Traversa G
COPD; 2018 Oct; 15(5):418-423. PubMed ID: 30822243
[TBL] [Abstract][Full Text] [Related]
11. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).
Vogelmeier CF; Asijee GM; Kupas K; Beeh KM
Adv Ther; 2015 Jun; 32(6):537-47. PubMed ID: 26100349
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of tiotropium/olodaterol Respimat
LaForce C; Derom E; Bothner U; Kloer IM; Trampisch M; Buhl R
Int J Chron Obstruct Pulmon Dis; 2018; 13():1819-1831. PubMed ID: 29910611
[TBL] [Abstract][Full Text] [Related]
14. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
Buhl R; Magder S; Bothner U; Tetzlaff K; Voß F; Loaiza L; Vogelmeier CF; McGarvey L
Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV
Calverley PMA; Mueller A; Fowler A; Metzdorf N; Wise RA
Ann Am Thorac Soc; 2018 Feb; 15(2):200-208. PubMed ID: 28957643
[TBL] [Abstract][Full Text] [Related]
16. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial.
Tashkin DP; Leimer I; Metzdorf N; Decramer M
Respir Res; 2015 Jun; 16(1):65. PubMed ID: 26031308
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of glycopyrrolate/eFlow
Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
[TBL] [Abstract][Full Text] [Related]
18. Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO
Wedzicha JA; Buhl R; Singh D; Vogelmeier CF; de la Hoz A; Xue W; Anzueto A; Calverley PMA
Adv Ther; 2020 Oct; 37(10):4266-4279. PubMed ID: 32776202
[TBL] [Abstract][Full Text] [Related]
19. Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study.
Ichinose M; Nishimura M; Akimoto M; Kurotori Y; Zhao Y; de la Hoz A; Mishima M
Int J Chron Obstruct Pulmon Dis; 2018; 13():2147-2156. PubMed ID: 30034230
[TBL] [Abstract][Full Text] [Related]
20. Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair
Yildiz P; Bayraktaroglu M; Gorgun D; Secik F
Int J Chron Obstruct Pulmon Dis; 2016; 11():2859-2867. PubMed ID: 27920513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
